Using BPC-157 or another peptide while experiencing headache, migraine changes, brain fog, or memory concerns? Neurologist Myrna Cardiel, MD, explains what the new study can—and cannot—tell us and how peptide use fits into an evaluation for headache or cognitive health, including concerns about Alzheimer’s disease and other dementias.

A newly published study in Headache offers a useful reminder that migraine and hormonal treatment have a more complicated relationship than is sometimes assumed.

Among 509 women seen in tertiary headache clinics, those using a stable hormonal treatment did not have significantly different migraine characteristics or preventive-treatment use compared with women who were not using hormones. The study does not prove that hormones cannot worsen migraine, nor was it specifically a study of contemporary menopausal hormone therapy. It does, however, challenge the idea that the presence of migraine alone should automatically lead us to blame—or discontinue—an otherwise stable hormonal regimen.

For women navigating migraine, contraception, perimenopause, or menopause, the more useful questions often include: Did the headaches change when the hormonal treatment was started or adjusted? Is migraine aura present? What hormone, dose, and route are being used? And what is the individual cardiovascular and vascular-risk profile?

The slides below summarize what this new study found, why it may matter clinically, and—equally importantly—what the research does not yet tell us.

In memory and brain-health care, no single test should be interpreted in isolation. A patient’s history, cognitive testing, blood biomarkers, MRI, and amyloid PET should tell a reasonably coherent story. When they do not, I do not assume that one result ends the discussion. A newly published analysis from the IDEAS study found that real-world amyloid PET interpretations are generally reliable—but disagreement between local and expert readers still occurs, particularly when reader confidence is lower. Large-scale 2026 data also support the value of standardized Centiloid quantification as an additional way to interpret amyloid PET burden.

That recently mattered in my own practice. A patient had an amyloid PET that was initially reported as negative. Later blood biomarkers strongly suggested amyloid pathology. Rather than dismissing the discrepancy, I requested additional review, including expert interpretation and quantitative Centiloid analysis. The result changed our understanding of the case. For me, the lesson is simple: good care sometimes means going back, asking another question, requesting expert review, and making sure the pieces truly fit together.

At Cardiel Precision Brain Health, my goal is not simply to order more tests. It is to look carefully at the entire clinical picture—and pursue clarification when the data do not make sense, especially when the answer may affect an important diagnosis or treatment decision.

Have cognitive concerns or conflicting test results? A comprehensive neurologic review may help clarify what the findings actually mean and what should come next.

Featured paper: Chiotis K, et al. Comparison of Expert Reads Versus Local Clinical Reads of Amyloid PET Scans in the IDEAS Study. Journal of Nuclear Medicine. Published September 10, 2026.

Do you think we still underestimate the vascular component of long-term brain health? This new study is a compelling reminder that cardiovascular, metabolic, and brain health may be far more interconnected than our traditional clinical silos suggest. Primary study: The Lancet Regional Health – Europe, 2026.
#BrainHealth #DementiaPrevention #Diabetes #PreventiveNeurology #CardiometabolicHealth

Four days. Two FDA clearances. One major shift in how Alzheimer’s disease may enter the diagnostic pathway. On August 20, the FDA cleared PrecivityAD2. On August 24, it cleared Roche’s automated Elecsys pTau217 assay. The headlines are exciting. My new article explains what changed, how the two tests differ and what primary care physicians, psychiatrists and other front-line clinicians should do next. The blood test is not the diagnosis. Used well, it may help us reach the right diagnosis sooner. #AlzheimersDisease #BloodBiomarkers #Neurology #CognitiveHealth #PrimaryCare #Psychiatry #PrecisionMedicine #BrainHealth

Could a medication prescribed for weight management also influence migraine? A nationwide Danish study of 189,392 adults found that semaglutide initiation was associated with triptan use approximately 7% below the projected level at 12 months. It is an encouraging signal—but not proof that semaglutide prevents migraine. In my new article, I examine what the study found, its important limitations, and why headache days, acute-medication use, hydration, and nutrition should be monitored when patients with migraine begin GLP-1 therapy. #Migraine #GLP1 #Semaglutide #Neurology #ObesityMedicine #BrainHealth

New research continues to highlight the connection between metabolic health and brain health. A newly published study in an Alzheimer’s disease mouse model found that semaglutide improved memory performance while reducing amyloid plaque burden, neuroinflammation, and blood–brain barrier dysfunction. While these findings do not prove benefit in humans, they add to growing evidence that metabolic therapies may influence pathways involved in brain aging and neurodegeneration. An important and rapidly evolving area of neurology, metabolism, and longevity.

It all begins here…Optimizing Brain Health: A Holistic Guide